Lymphoma Research Foundation Press Room:

On Monday, March 23, 2009, the U.S. Food and Drug Administration (FDA) approved THERAKOS CELLEX Photopheresis System for the palliative (reducing the severity of symptoms) treatment of cutaneous T-cell lymphoma (CTCL) that are unresponsive to other forms of treatment.

CTCL represents a spectrum of T-cell lymphomas that arise in the skin. The most common type is mycosis fungoides, which is often indolent. The skin may have localized, thickened patches that appear reddish. If the cells are found in the blood, this disease is more aggressive and may be called Sezary Syndrome. CTCL comprises about 2 percent to 3 percent of all non-Hodgkin lymphomas.

To learn more about CTCL, please visit the Cutaneous Lymphoma Foundation online.
To read the press release issued by Therakos, please click here.